Verastem Q4 2025 Earnings Preview
Source: SeekingAlpha
2026-03-03 17:35:57 ET
More on Verastem
- Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC
- Verastem posts preliminary 2025 revenue, plans clinical updates in 2026
- Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC
- Seeking Alpha’s Quant Rating on Verastem
- Historical earnings data for Verastem
Read the full article on Seeking Alpha
For further details see:
Verastem Q4 2025 Earnings Preview
Verastem Inc.
NASDAQ: VSTM
VSTM Trading
4.32% G/L:
$6.40 Last:
844,560 Volume:
$5.99 Open:
VSTM Latest News
VSTM Stock Data
$424,027,638
66,108,246
1.4%
15
N/A
Biotechnology & Life Sciences
Healthcare
US
Needham
